The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10232 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial

Not Open Access | Asymptomatic malaria in the clinical and public health context

December 2, 2019 - 17:45 -- NOT Open Access
Author(s): 
Cheaveau J, Mogollon DC, Mohon MAN, Golassa L, Yewhalaw D, Pillai DR
Reference: 
Expert Rev Anti Infect Ther. 2019 Nov 21:1-14.

Historically, the global community has focused on the control of symptomatic malaria. However, interest in asymptomatic malaria has been growing, particularly in the context of malaria elimination.

Decreased K13 Abundance Reduces Hemoglobin Catabolism and Proteotoxic Stress, Underpinning Artemisinin Resistance

December 2, 2019 - 14:43 -- Open Access
Author(s): 
Yang T, Yeoh LM, Cobbold SA, et al.
Reference: 
Cell Rep. 2019 Nov 26;29(9):2917-2928.e5

Increased tolerance of Plasmodium falciparum to front-line artemisinin antimalarials (ARTs) is associated with mutations in Kelch13 (K13), although the precise role of K13 remains unclear. Here, we show that K13 mutations result in decreased expression of this protein, while mislocalization of K13 mimics resistance-conferring mutations, pinpointing partial loss of function of K13 as the relevant molecular event.

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection

November 30, 2019 - 20:12 -- Open Access
Author(s): 
Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S
Reference: 
PLoS Negl Trop Dis. 2019 Nov 21;13(11):e0007890.

Recent outbreaks of the Ebola virus (EBOV) have focused attention on the dire need for antivirals to treat these patients. We identified pyronaridine tetraphosphate as a potential candidate as it is an approved drug in the European Union which is currently used in combination with artesunate as a treatment for malaria (EC50 between 420 nM-1.14 μM against EBOV in HeLa cells).

NOT Open Access | Antimalarial herbal remedies of Bukavu and Uvira areas in DR Congo: An ethnobotanical survey

November 28, 2019 - 06:32 -- NOT Open Access
Author(s): 
Mboni Henry Manya, Flore Keymeulen, Jérémie Ngezahayoc, Amuri Salvius Bakaria, Mutombo Emery Kalonda, Byanga Joh Kahumba, Pierre Duez, Caroline Stévigny, Simbi Jean-Baptiste Lumbu
Reference: 
Journal of Ethnopharmacology, 22 November 2019, 112422

The main objective of the present study was to collect and gather information on herbal remedies traditionally used for the treatment of malaria in Bukavu and Uvira, two towns of the South Kivu province in DRC.

Country: 

The genomic architecture of antimalarial drug resistance

November 26, 2019 - 20:17 -- Open Access
Author(s): 
Annie N Cowell, Elizabeth A Winzeler
Reference: 
Briefings in Functional Genomics, Volume 18, Issue 5, September 2019, Pages 314–328

Plasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that cause the majority of cases of human malaria, have developed resistance to nearly all known antimalarials. The ability of malaria parasites to develop resistance is primarily due to the high numbers of parasites in the infected person’s bloodstream during the asexual blood stage of infection in conjunction with the mutability of their genomes.

Not Open Access | Phenotypic Screening of Small Molecules with Antimalarial Activity for Three Different Parasitic Life Stages.

May 10, 2018 - 15:56 -- NOT Open Access
Author(s): 
Kato N, March S, Bhatia SN, Marti M
Reference: 
Methods Mol Biol. 2018;1787:41-52

Despite a renewed effort to identify compounds with antimalarial activity, the drug discovery and development pipeline lacks target diversity and availability of compounds that target liver- and gametocyte-stage parasites. 

A novel validated assay to support the discovery of new anti-malarial gametocytocidal agents

July 27, 2016 - 06:59 -- Open Access
Author(s): 
Noemí Bahamontes-Rosa, María G. Gomez-Lorenzo, Joël Lelièvre, Ane Rodriguez Alejandre, María Jesus Almela, Sonia Lozano, Esperanza Herreros and Francisco-Javier Gamo
Reference: 
Malaria Journal 2016 15:385, 22 July 2016

This study describes a novel assay for characterizing the activity of anti-malarial drugs against the later stages of P. falciparum gametocyte development using qPCR in genetically unmodified parasites.

Medical Condition: 

Examining Plasmodium falciparum and P. vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction

April 21, 2016 - 16:26 -- Open Access
Author(s): 
Lo E, Nguyen J, Oo W, Hemming-Schroeder E, Zhou G, Yang Z, Cui L, Yan G
Reference: 
BMC Infectious Diseases 2016, 16 :154 (16 April 2016)

This study aims to examine clearance time of P. falciparum and P. vivax parasitemia as well as putative gene mutations associated with residual or recurred parasitemia in Myanmar.

A combined within-host and between-hosts modelling framework for the evolution of resistance to antimalarial drugs.

April 19, 2016 - 14:49 -- Open Access
Author(s): 
Legros M, Bonhoeffer S
Reference: 
J R Soc Interface. 2016 Apr;13(117)

We show that the spread of resistance is generally less likely in areas of intense transmission, and therefore of increased competition between strains, an effect exacerbated when costs of resistance are higher. 

Not Open Access | Artemisinin nanoformulation suitable for intravenous injection: Preparation, characterization and antimalarial activities

November 25, 2015 - 08:36 -- NOT Open Access
Author(s): 
Nehal Ibrahim, Hany Ibrahim, Alicia Moreno Sabater, Dominique Mazier, Alexis Valentin, Françoise Nepveu
Reference: 
International Journal of Pharmaceutics, Volume 495, Issue 2, 30 November 2015, Pages 671-679

Here, we report the preparation, characterization, and in vitro and in vivo biological evaluation of biodegradable albumin-bound artemisinin nanoparticles. 

Pages

Subscribe to RSS - antimalarial